These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25256060)

  • 1. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
    Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
    J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
    Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical values for abnormal ¹⁸F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma.
    Lee HS; Kim JS; Roh JL; Choi SH; Nam SY; Kim SY
    Eur J Radiol; 2014 Aug; 83(8):1455-60. PubMed ID: 24929443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.
    Balogova S; Périé S; Kerrou K; Grahek D; Montravers F; Angelard B; Susini B; El Chater P; St Guily JL; Talbot JN
    Mol Imaging Biol; 2008; 10(6):364-73. PubMed ID: 18668293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
    Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
    AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
    Ong SC; Schöder H; Lee NY; Patel SG; Carlson D; Fury M; Pfister DG; Shah JP; Larson SM; Kraus DH
    J Nucl Med; 2008 Apr; 49(4):532-40. PubMed ID: 18344440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
    Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
    Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of D-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine.
    Tsukada H; Sato K; Fukumoto D; Nishiyama S; Harada N; Kakiuchi T
    J Nucl Med; 2006 Apr; 47(4):679-88. PubMed ID: 16595503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
    Paidpally V; Tahari AK; Lam S; Alluri K; Marur S; Koch W; Wahl RL; Subramaniam RM
    J Nucl Med; 2013 Dec; 54(12):2039-45. PubMed ID: 24101687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions].
    Wang Q; Huang LL; Yue MG; Qin SL; Wang Y; Nie YX; Zhang CQ; Liang TJ; Zhao YM
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):924-7. PubMed ID: 17533745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.